Ultra-compact TIGRa gene activator switches on multiple genes from one AAV vector
Stanford researchers built TIGRa, a gene activator under half the size of dSpCas9 systems. It fits in one AAV and activates multiple genes, and in mice it protected retinal neurons.
Summary
Turning on several protective genes at once is attractive for diseases like glaucoma, but CRISPR-based activators are too big to fit in a single AAV vector. Researchers screened miniature RNA-guided proteins and built TIGRa from the ~300-amino-acid TasR protein, which processes its own short guide array. Fused to compact activation domains, TIGRa matched or approached dSpCas9 activators in cell culture while being far smaller. Engineered variants (Mini, Pro, Ultra) trade size against potency. According to the abstract, TIGRa activated up to 12 genes from one construct, helped reprogram human fibroblasts into iPSCs, and, delivered by a single AAV, activated CaMKII to protect retinal ganglion cells and preserve vision in a mouse injury model. The work is preclinical, but it offers a compact, multiplexable platform for gene regulation therapies.
Detailed Summary
Many age-related and degenerative diseases, including glaucoma and other optic neuropathies, probably need coordinated changes in several survival and repair pathways rather than a single-gene fix. Programmable gene activators can raise the expression of a cell's own genes. But the standard dSpCas9-based CRISPR activators (1368 amino acids) are too large for a single AAV vector, which holds about 4.7 kb. Larger activators therefore need dual-vector delivery, and compact alternatives have not offered scalable multiplexing.
The Stanford team screened eight nuclease-dead miniature RNA-guided proteins (337-506 amino acids) fused to the VPR activation domain, targeting the HBB promoter in HEK293T cells. Only dead ParTasR from the TIGR-TasR family gave robust activation (up to 7486-fold, versus 8676-fold for the dCasMINI-VPR control). This became TIGRa. It uses a short 36-nt tigRNA, has no strict PAM requirement, and prefers an 18-nt target with roughly 50-67% GC content. It activated 20 of 24 tested HBB sites, 10 of them by more than 100-fold, and also worked at ASCL1, IL1RN and HBG1. Across four loci, TIGRa reached about 0.74 of dSpCas9 activity and beat dCasMINI, dCas12a and hyperdCas12a activators by 2.45-3.55-fold.
The team then swapped in smaller activation domains and added auxiliary DNA-binding domains. TIGRa-Mini (NFZ domain, 540 aa) is about a quarter the size of dSpCas9 and retained activity near the original, at about 0.72-fold. TIGRa-Pro (NFZ plus p65, 727 aa) was about 2.3-fold more active than TIGRa. TIGRa-Ultra (Aho7c DNA-binding domain added) was about 4-fold more active. Whole-transcriptome RNA-seq showed that all variants selectively raised the intended HBB target, with off-target profiles broadly comparable to the high-specificity dCasMINI-VPR.
For multiplexing, a native array of four 36-nt tigRNAs (414 bp) matched a conventional four-U6-promoter design (1224 bp) in activation (1.16-fold) and outperformed ribozyme-processed designs. Small RNA-seq showed that mammalian cells process the array into individual tigRNAs. The abstract (the supplied full text cuts off here) reports that this enabled simultaneous activation of up to 12 endogenous genes from one compact construct, efficient reprogramming of human fibroblasts into induced pluripotent stem cells, and in vivo activation of endogenous CaMKII by an all-in-one AAV-TIGRa vector. In a mouse model of NMDA-induced retinal injury, this promoted retinal ganglion cell survival and preserved visual function.
If these results hold up, TIGRa could be a practical route to multi-gene therapeutic regulation with single-vector delivery. Caveats include the preclinical setting: most characterization used HEK293T cells and a single acute mouse injury model. Activation still varies by target site, and long-term safety, immunogenicity, and specificity in relevant human tissues remain untested. The details of the in vivo and reprogramming experiments were not available in the supplied text.
Key Findings
- Dead ParTasR-VPR reached up to 7486-fold HBB activation, comparable to dCasMINI-VPR (8676-fold), while other miniature nucleases showed weak activity.
- TIGRa reached about 0.74-fold of dSpCas9 activation and beat dCasMINI and Cas12a-based activators by 2.45-3.55-fold across four loci.
- TIGRa-Mini (540 aa) is a quarter of dSpCas9's size; TIGRa-Pro and TIGRa-Ultra raised activity about 2.3- and 4-fold over TIGRa.
- A native four-tigRNA array (414 bp) matched a 1224-bp U6-based design, enabling reported activation of up to 12 genes from one construct.
- Single-AAV TIGRa activated CaMKII in mice, promoting retinal ganglion cell survival and preserving vision after NMDA injury (per abstract).
Methodology
Preclinical tool-development study. Researchers screened nuclease-dead miniature RNA-guided proteins fused to activation domains in HEK293T cells (RT-qPCR, whole-transcriptome and small RNA-seq), then engineered variants and benchmarked them against CRISPRa systems. Applications included iPSC reprogramming of human fibroblasts and single-AAV delivery in a mouse NMDA retinal injury model.
Study Limitations
Most characterization used HEK293T cells with a handful of loci, and activation efficiency varied across tigRNA sites. In vivo evidence rests on one acute mouse injury model, with no long-term safety, immunogenicity, or off-target assessment in relevant tissues. This summary also relies on the abstract for the 12-gene multiplexing, iPSC, and retinal results, because the supplied full text was truncated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: